Please visit our MS learning channel on YouTube, which provides hundreds of MS related topics from many of our video recorded education programs and archived here: -- Be empowered with MS views and news. Opt-in with us:

~~ Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Wednesday, May 20, 2015

New therapy could halt multiple sclerosis progress

"We believe we have identified the first therapy that will impact the quality of life of people with multiple sclerosis by significantly reducing the disability and the disease's progression," said Dr. Alexandre Prat, a professor in the Department of Neurosciences at the University of Montreal.
By Stephen Feller   |   May 20, 2015

Multiple sclerosis is the result of lymphocytes penetrating the brain-blood barrier and disrupting the transmission of nerve impulses. Researchers believe they have identified a primary molecule that helps this to happen. Image by Ralwel/Shutterstock

MONTREAL, May 20 (UPI) -- Researchers at the University of Montreal have discovered a treatment that can potentially stop the progression of multiple sclerosis.
The melanoma cell adhesion molecule, or MCAM, was found to be a crucial element in the attacks on the nervous system which slowly incapacitate people with multiple sclerosis. In vitro tests in humans, as well as tests in mice, showed that MCAM can be blocked, delaying onset of the disease and potentially slowing its progress.

 Keep CURRENT with MS Views and NewsOPT-IN here


No comments: